Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases... Show more
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AMLX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AMLX broke above its upper Bollinger Band on March 07, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AMLX's RSI Oscillator exited the oversold zone, of 25 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on March 06, 2025. You may want to consider a long position or call options on AMLX as a result. In of 48 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for AMLX just turned positive on March 06, 2025. Looking at past instances where AMLX's MACD turned positive, the stock continued to rise in of 26 cases over the following month. The odds of a continued upward trend are .
AMLX moved above its 50-day moving average on March 11, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where AMLX advanced for three days, in of 190 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 123 cases where AMLX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.952) is normal, around the industry mean (11.661). P/E Ratio (2.686) is within average values for comparable stocks, (63.786). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.805). Dividend Yield (0.000) settles around the average of (0.025) among similar stocks. P/S Ratio (2.831) is also within normal values, averaging (239.652).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. AMLX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AMLX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Industry Biotechnology
A.I.dvisor indicates that over the last year, AMLX has been closely correlated with XOMAO. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if AMLX jumps, then XOMAO could also see price increases.
Ticker / NAME | Correlation To AMLX | 1D Price Change % | ||
---|---|---|---|---|
AMLX | 100% | -1.09% | ||
XOMAO - AMLX | 68% Closely correlated | -0.03% | ||
IKNA - AMLX | 54% Loosely correlated | -0.74% | ||
XOMAP - AMLX | 51% Loosely correlated | N/A | ||
JAZZ - AMLX | 43% Loosely correlated | +1.40% | ||
VNDA - AMLX | 42% Loosely correlated | +1.42% | ||
More |